nect Biopharma (US:CNTB) Globenewswire·2025-09-29 13:00Core Insights - Connect Biopharma presented data on rademikibart, showing significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers [1][2][3] - The company anticipates reporting topline data from ongoing Phase 2 Seabreeze STAT studies for asthma and COPD in the first half of 2026 [1][2] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, headquartered in San Diego, California [6] - The company is advancing rademikibart, a next-generation anti-IL-4Rα antibody, through global clinical studies targeting acute exacerbations of asthma and COPD [6] Clinical Trial Results - Rademikibart demonstrated rapid and sustained improvements in lung function, with a 507 mL increase in prebronchodilator FEV1 for patients with high eosinophil counts and high FeNO levels at Week 24 [3] - A significant reduction in asthma exacerbations was noted, with a 63% reduction in patients with high eosinophils and a 69% reduction in those with high FeNO [3] - The Phase 2b trial results indicated that rademikibart's efficacy varied based on regional differences, with greater benefits observed in the overall trial population compared to the Polish subgroup [3][4] Future Development Plans - The data from the Phase 2b study will inform the clinical development plans and site strategies for ongoing studies [2][4] - Connect Biopharma is collaborating with Simcere in China for the development of rademikibart [6]